Itraconazole and domperidone: a placebo-controlled drug interaction study

作者：Yoshizato Tsuneaki; Kotegawa Tsutomu^*; Imai Hiromitsu; Tsutsumi Kimiko; Imanaga Junko; Ohyama Tetsuji; Ohashi Kyoichi

来源：European Journal of Clinical Pharmacology, 2012, 68(9): 1287-1294.

DOI：10.1007/s00228-012-1258-x

• Domperidone
• Itraconazole
• CYP3A
• MDR1
• Prolactin

To determine the influence of itraconazole on the pharmacokinetics, and the CNS and prolactin-elevating effects of domperidone in humans.
Fifteen healthy volunteers received either itraconazole (200 mg daily) or placebo for 5 days with a double blind, randomized, cross-over design. A single oral 20-mg dose of domperidone was administered to subjects on day 5. Plasma domperidone and serum prolactin concentrations were measured. The effects of domperidone on CNS were also assessed using self-rating scales and electroencephalography.
Itraconazole significantly increased domperidone AUC(0-a) (3.2-fold) and C-max (2.7-fold) compared with placebo, but had no significant effect on the elimination half-life of domperidone. The CNS effects of domperidone assessed by self-rating of mood and electroencephalography, and the prolactin-elevating effect, were not significantly affected by itraconazole. A counterclockwise hysteresis was evident in the relationship between plasma domperidone and serum prolactin concentrations. Itraconazole shifted the hysteresis to the right. Concentration-effect modeling procedures yielded a significant linear relationship between hypothetical effect site domperidone concentrations and prolactin levels. Itraconazole reduced the slope of the linear relationship.
Itraconazole significantly increased plasma domperidone concentrations. The interaction is probably mainly due to a reduced first pass elimination by inhibition of CYP3A and/or MDR1. The clinical significance of the altered relationship between domperidone concentrations and prolactin levels caused by itraconazole is still to be determined.

• 出版日期2012-9